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Background: Heparanase is an endo-β-D-glucuronidase that cleaves heparan sulfate chains of proteoglycans,
resulting in the disassembly of the extracellular matrix. Heparanase has a central role in the development of various
tumors, and its expression has been associated with increased tumor growth, angiogenesis and metastasis, but
there is insufficient information about the function of heparanase in sarcomas.
Study aims: 1) To evaluate heparanase levels in adult soft tissue sarcomas (STS); 2) To examine the correlation
between heparanase levels and pathological and clinical parameters and treatment outcome.
Methods: Pathological specimens of primary or metastatic STS were subjected to immunohistochemical analysis
applying an anti-heparanase antibody. The clinical and the pathological data, together with the data of heparanase
levels, were evaluated in a logistic regression model for tumor recurrence and survival.
Results: One hundred and one samples were examined, 55 from primary tumors and 46 from metastatic sites. A
high expression of heparanase was observed in 29 (52.7%) and 22 specimens (47.8%), respectively. There was no
statistically significant difference between heparanase expressions in the primary vs. metastatic sites of tumors.
Moreover, no correlation was observed between heparanase staining and tumor aggressiveness, tumor recurrence
or patient survival in various groups of patients.
Conclusion: Expression of heparanase was observed in 50% of the STS, in various histological subtypes. A larger
study with homogenous groups of specific sub-types of STS or stages of disease is required to validate
over-expression of heparanase as a marker of disease aggressiveness.
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Heparanase is an endo-β-glucuronidase that cleaves hep-
aran sulfate (HS) side chains, presumably at sites of low
sulfation, releasing saccharide products with appreciable
size (4–7 kDa) and biological activity.
“Enzymatic degradation of HS contributes to disassembly
of extracellular matrix (ECM) and is therefore involved in
fundamental biological phenomena associated with tissue
remodelling and cell migration, including inflammation,
neo-angiogenesis and metastases formation [1-4]”.
The clinical significance of the enzyme in tumor
progression emerged from a systematic evaluation of
heparanase expression in primary human tumors.* Correspondence: g_barsela@rambam.health.gov.il
1Division of Oncology, Rambam Health Care Campus, 8 Ha’Aliyah Street,
Haifa 35254, Israel
Full list of author information is available at the end of the article
© 2014 Kazarin et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Immunohistochemistry, in situ hybridization, RT-PCR and
real time-PCR analyses revealed that heparanase is up-
regulated in essentially all human carcinomas examined
and in some hematological malignancies (i.e. myeloma)
[2,5-7]. Notably, increased heparanase levels were most
often associated with reduced patient survival post-surgery,
increased tumor metastasis and higher microvessel density
[2,7,8], thus critically supporting the intimate involvement
of heparanase in tumor progression and encouraging the
development of heparanase inhibitors as anti-cancer thera-
peutics [9,10]. Importantly, heparanase up-regulation in
human tumors (i.e. head & neck, tongue, hepatocellular,
breast and gastric carcinomas) is associated with tumors
larger in size [2,8]. Likewise, heparanase over-expression
enhanced [11-13], while local delivery of anti-heparanase
siRNA inhibited [14] the progression of tumor xenografts,
implying that heparanase function is not limited to tumorLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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primary lesion [12].
While the clinical significance of heparanase in human
carcinomas is well documented and anti-heparanase
compounds are being tested in clinical trials [15], the role
of heparanase in mesenchymal tumors such as sarcoma
has not been investigated in detail [16].
Suppressing heparanase levels as a treatment approach
was tested using pre-clinical models in various forms of
cancer [17-19]. A chemical preparation known as PI-88,
which suppresses heparanase activity, was tested in a
number of Phase 2 clinical studies and showed some
activity when used in the treatment of metastatic mel-
anoma [17], and in conjunction with docetaxel to treat
hormone-resistant prostate cancer [18].
The incidence of sarcomas constitutes approximately
1% in adults and up to 12% in children of all malignan-
cies. Approximately 80% have soft tissue origins while
the rest originate in the bone. Soft tissue sarcomas (STS)
are divided by the World Health Organization (WHO)
into more than 50 sub-groups and types. The presence
of metastases during the initial diagnosis is uncommon.
However, the potential for metastatic disease is elevated
according to tumor grade, depth of penetration, and
histology [20]. In a break-through laboratory study on
animals based on STS models, the experimental drug,
heparanase inhibitor SST0001,was administered by sub-
cutaneous injections to tumors with increased heparanase
expression, in conjunction with antiangiogenic agents
(bevacizumab, sunitinib). The purpose of this treatment
was to suppress heparanase activity, resulting in the sup-
pression of growth factors such as VEGF, HGF, and PDGF.
The results of this study were positive and complete re-
mission was noted in some of the cases [19].
The primary goal of the current study was to examine
the expression of heparanase in soft tissue sarcomas in
adults according to common histological sub-types. The
secondary goal was to examine the possibility that the
over-expression of heparanase serves as a prognostic
index in the development of STS metastases.
Materials and methods
Sample size
Following approval of the study by the Rambam Health
Care Campus Helsinki Committee, 101 biopsies from
adult patients diagnosed with STS in the years 2001–
2010 and under the care of the Division of Oncology at
Rambam Health Care Campus were collected. A number
of samples from common types of histology were ran-
domly selected. Data was collected from the clinical
follow-up, including demographic and clinical charac-
teristics, stage of disease (TNM) at the time of diagnosis,
evidence of recurrence, appearance of outlying metastases,
and patient survival.Patients were excluded if only partial data was available
in the medical file, or if it was impossible to prepare enough
slides from the pathological block.
Biopsy samples were taken from a primary tumor or
from metastases. In 10 cases, the biopsies were taken
at different stages of the disease, from a primary tumor
and from the metastatic lesion. Biopsies were subjected
to immunostaining, applying an antibody (#733) raised
against the N-terminal region of heparanase [21], essentially
as described [22,23]. Briefly, slides were deparaffinized,
rehydrated, and subjected to antigen retrieval by boil-
ing (20 min) in 10 mM citrate buffer, pH 6.0. Following
washes with phosphate buffered saline (PBS), slides were
incubated with 10% normal goat serum (NGS) in PBS
for 60 min to block non-specific binding and incubated
(20 h, 4°C) with antibody 733, diluted 1:100 in blocking
solution. Slides were extensively washed with PBS con-
taining 0.01% Triton X-100 and incubated with a sec-
ondary reagent (Envision) according to manufacturer’s
(Dako, Glostrup, Denmark) instructions. Following
additional washes, color was developed with AEC reagent
(Dako), sections were counterstained with hematoxylin
and mounted, as described [21]. Immunostained speci-
mens were examined by a senior pathologist (IN) who
was blind to the clinical data of the patients and scored
according to the intensity of staining (0: none, +1:
weak-moderate; +2: strong). Specimens that were simi-
larly stained with mouse IgG, or by applying the above
procedure but lacking the primary antibody, yielded no
detectable staining.
Processing results and statistics
The frequency of over-expression of heparanase based
on sub-types of sarcoma and in groups of patients with
metastases or with primary cancer was calculated. Using a
bivariate logistic regression, a comparison was made be-
tween the demographic data, the disease characteristics and
the degree of heparanase staining, disease recurrence and
survival using the Chi-square test. Confidence Interval (CI)
(95%) was calculated according to the sample size and the
number of cases with heparanase over-expression.
The level of significance selected to check the various
statistical hypotheses in this study was set at p ≤ 0.05.
The data was processed using SPSS statistical software,
version 18.0 (Chicago, IL).
Results
One hundred and one patients were included in the study.
The main patient demographic and clinical characteristics
are summarized in Table 1. Fifty-eight were male. Median
age at diagnosis was 63 years; 59 (58.6%) patients were over
the age of 60. Thirty percent of the patients had malignant
fibrous histiocytoma (MFH) and 22% of the patients were
diagnosed with a given sarcoma with no defined sub-type
Table 1 Demographic and clinical data for 101 patients related to over-expression of heparanase based on IHC staining
Characteristic No. of patients outof entire group
No. of patients with over-expressed
heparanase, according to sub-groups (%) P value
Age
<40 21 6 (28.5%)
0.65
40-59 21 11 (52.4%)
60-69 30 16 (53.3%)
>70 29 12 (43.3%)
Gender
Male 58 25 (43.1%)
0.88
Female 43 20 (46.5%)
Pathological type
Malignant fibrous histiocytoma 30 12 (40%)
0.87
Liposarcoma 16 8 (50%)
Leiomyosarcoma 13 6 (46.1%)
Angiosarcoma 4 1 (25%)
Chondrosarcoma 7 5 (71.4%)
Sinovial sarcoma 9 4 (44.4%)
NOS 22 9 (40.9%)
Grade
Low 28 12 (42.8%)
0.44Intermediate 6 2 (33.3%)
High 67 31 (46.2%)
Stage
I 29 13 (44.8%)
0.55
II 7 1 (14.3%)
III 46 20 (43.4%)
IV 19 11 (57.9%)
Total 101 51 (50.5%)
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grade sarcomas. Nearly 20% of the patients had metastatic
disease at the time of diagnosis. All 101 histological
specimens of STS were stained for heparanase as de-
scribed above, 55 from primary tumors and 46 from
metastatic sites. A high expression of heparanase was
seen in 29 (52.7%) and 22 specimens (47.8%), respectively.
Figure 1(a-c) shows different samples of STS stained for
heparanase, with negative, low and positive heparanase
expression accordingly.
Table 1 summarizes the correlation between over-
expression of heparanase in the pathological samples
and the clinical and pathological characteristics of the
patients. The staining was graded according to the strength
of the color and its perimeter, as detailed in Methods
and Materials. More than 95% of the pathological samples
stained for heparanase in over 50% of the cells; therefore,
it was not possible to analyze the data based on the extent
of the staining. In general, heparanase over-expression was
seen in nearly 50% of the samples and in all sub-groups of
histological sub-types, pathological grade or stage of disease.
Estimation of the correlation between the color strength
of the stain for heparanase and the risk of the disease
recurring was performed on 55 patients with biopsysamples taken from a primary tumor following radical
surgery to remove the tumor.
During the follow-up period over at least five years from
the time of the surgery, the disease recurred in 50% of the
patients. In half the patients whose disease recurred during
the clinical follow-up period, strong color staining for
heparanase was observed, although the same was also ob-
served in 12 samples from 29 patients whose disease did
not recur. Accordingly, the sensitivity and specificity of the
strong color staining for heparanase as a predictor for the
recurrence of the disease are 0.50 and 0.59, respectively.
Table 2 summarizes the risk for disease recurrence ac-
cording to demographic and histologic parameters for each
group. A statistically significant risk for disease recurrence
was found only to grade and stage of the disease.
In 10 cases, biopsy specimens from metastases were
compared to the surgical specimens of the primary tu-
mors. In 8/10 cases, no difference in the level of stain-
ing was observed. The sample was too small for any
statistical analysis (Table 3).
Discussion
The primary endpoint of the current study was to check
the expression of heparanase using immunohistochemistry
Figure 1 Examples of heparanase staining in different soft
tissue sarcoma types. a: Negative heparanase staining in
leiomyosarcoma, (original magnification × 200). b: Weak cytoplasmic
heparanase staining in synovial sarcoma, (original magnification × 200).
c: Strong cytoplasmic heparanase staining in malignant fibrous
histiocytoma, (original magnification × 200).
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in adults. A limited number of studies have checked hepar-
anase levels in different sarcoma types, including a study by
Shafat et al. [16], which examined the level of heparanase
in pathological samples taken from children with Ewing’s
sarcoma. Heparanase levels were evaluated using immuno-
histochemistry of 69 pathological samples utilizing method-
ology similar to that applied in this study. Over-expression
of heparanase was seen in 51% of the cases. In another
study, Masola et al. examined the expression of heparanase
in 15 pathological samples and in the blood of children
with rhabdomyosarcoma [24]. While pathological speci-
mens were stained positive for heparanse, the level of
the enzyme in the blood was similar to healthy controls.
The current study is the first attempt to evaluate the level
of heparanase over-expression in sarcoma that frequently
occurs in adults, showing a similar percentage of over-
expression as in children’s sarcoma subtypes.
A number of studies have found high levels of heparanase
in tumor cells in comparison to normal and pre-cancerous
cells [25,26]. For example, Maxhimer et al. reported a high
prevalence of heparanase expression in breast tumor tis-
sue at advanced stage (53%), in comparison to tumors at
an early stage of the disease (23%) and in healthy breast
tissue (0%) [27].
A study by Friedmann et al. [22] examined the level of
heparanase in the mucous membrane of the colon and
colon polyps and neoplasm, using an mRNA probe directed
against heparanase (in situ hybridization) and immuno-
staining. Heparanase expression increased when the level
of cellular differentiation was lower and the dysplasia was
higher, while there was almost no heparanase expression
in normal cells. High expression of heparanase was found
in primary colon cancer as well as in colon cancer metas-
tases to the lungs, liver, and lymph nodes. In the sarcomas,
the tissue of mesenchymal origin where the tumor forms
is usually not defined. It is therefore not possible to docu-
ment the heparanase level during the developmental
stages of the tumor. As opposed to breast carcinoma but
similar to colon carcinoma, the current study found a
similar rates of heparanase over-expression in primary
tumors and metastases.
Most of the studies that addressed the question of
heparanase expression were carried out on epithelial
tumors. A large number of these studies found a direct
connection between the enzyme level in the tumor and the
aggressiveness of the disease, implying that the heparanase
Table 2 Disease recurrence according to demographic and histologic parameters, in 55 patients
Characteristic No. of patients out
of entire group (%)
No. of patients with recurrent




<40 13 (24%) 5 (38.5%)
0.73
40-59 9 (16%) 4 (44.4%)
60-69 14 (25%) 8 (57.1%)
>70 19 (35%) 10 (52.6%)
Gender
Male 33 (60%) 16 (48.5%)
0.44
Female 22 (40%) 12 (54.2%)
Pathological type
Malignant fibrous histiocytoma 19 (35%) 12 (66.7%)
0.67
Liposarcoma 8 (15%) 3 (37.5%)
Leiomyosarcoma 6 (11%) 4 (66.6%)
Angiosarcoma 2 (4%) 0
Chondrosarcoma 5(8%) 1 (20%)
Synovial sarcoma 4 (7%) 3 (75%)
NOS 11 (20%) 5 (45.5%)
Grade
Low 15 (27%) 0
0.01>Intermediate 3 (5%) 1 (33%)
High 37 (67%) 27 (73%)
Stage
I 18 (33%) 1 (5.5%)
0.01>II 4 (7%) 3 (75%)
III 33 (60%) 24 (73%)
Level of heparanase expression No staining 5 (9%) 3 (60%)
0.77Weak staining 18 (33%) 10 (55%)
Strong staining 32 (58%) 15 (47%)
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secondary end-point of the current study attempts to test
the prognostic significance of heparanase expression after
ascertaining that the prognostic factors known from the lit-
erature (grade and stage) are indeed repeated in this study.
No correlation was found between heparanase levels and
prognosis. It is possible that, due to the high level of hetero-
geneity of the various histological types of sarcoma, a much
larger sample group would be required to reveal the role of
heparanase as a prognostic factor in sarcomas. In contrast
to the current study, the study by Shafat et al. [16] found a
correlation between heparanase level and poor prognostic
factors (tumor size and patient age at time of diagnosis) in
Ewing’s sarcoma. It is noteworthy that there is a significant
difference between the course of the disease, prognosis, andTable 3 Level of heparanase staining in samples from the
primary tumor and metastases of the same patients






Strong (2) 7 5
Weak (0–1) 3 5
Total 10 10treatment for patients with STS in adults and common sar-
comas in children [28].
Conclusions
Heparanase expression was increased in more than 50%
of the STS cases. We were unable to find a correlation
between heparanase staining intensity and recurrence of
the disease. In light of the development of heparanase
inhibitors as novel treatment options, it is important to
carry out further studies, which should include larger
patient groups with specific sub-type sarcomas, in order
to better delineate the significance of heparanase in STS.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
OK carried out the histological staining and collected the clinical data. NI
was responsible for the heparanase laboratory, including the staining, and
helped to draft the manuscript. IN and OBI deciphered the stained samples.
IV participated in the design of the study and helped to draft the
manuscript. GB analyzed the pathological and clinical data, made the
statistical analysis, and wrote the manuscript. All authors read and approved
the final manuscript.
Author details
1Division of Oncology, Rambam Health Care Campus, 8 Ha’Aliyah Street,
Haifa 35254, Israel. 2Cancer and Vascular Biology Research Center, The Bruce
Kazarin et al. Journal of Experimental & Clinical Cancer Research 2014, 33:39 Page 6 of 6
http://www.jeccr.com/content/33/1/39Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa,
Israel. 3Pathology Institute, Rambam Health Care Campus, Haifa, Israel.
Received: 27 March 2014 Accepted: 30 April 2014
Published: 10 May 2014
References
1. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I:
Proteoglycans in health and disease: new concepts for heparanase function
in tumor progression and metastasis. FEBS J 2010, 277:3890–3903.
2. Ilan N, Elkin M, Vlodavsky I: Regulation, function and clinical significance
of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell
Biol 2006, 38:2018–2039.
3. Parish CR, Freeman C, Hulett MD: Heparanase: a key enzyme involved in
cell invasion. Biochim Biophys Acta 2001, 1471:M99–M108.
4. Vlodavsky I, Friedmann Y: Molecular properties and involvement of
heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001,
108:341–347.
5. Fux L, Ilan N, Sanderson RD, Vlodavsky I: Heparanase: busy at the cell
surface. Trends Biochem Sci 2009, 34:511–519.
6. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I: The heparanase system
and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis
Rev 2011, 30:253–268.
7. Vreys V, David G: Mammalian heparanase: what is the message? J Cell Mol
Med 2007, 11:427–452.
8. Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N, Elkin M:
Significance of heparanase in cancer and inflammation. Cancer
Microenviron 2012, 5:115–132.
9. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt
R, Ferro V, Bytheway I: PG545, a dual heparanase and angiogenesis
inhibitor, induces potent anti-tumour and anti-metastatic efficacy in
preclinical models. Br J Cancer 2011, 104:635–642.
10. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C,
Carminati P, Tortoreto M, Zunino F, Vlodavsky I, Sanderson RD, Yang Y:
SST0001, a chemically modified heparin, inhibits myeloma growth and
angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin
Cancer Res 2011, 17:1382–1393.
11. Barash U, Cohen-Kaplan V, Arvatz G, Gingis-Velitski S, Levy-Adam F, Nativ O,
Shemesh R, Ayalon-Sofer M, Ilan N, Vlodavsky I: A novel human heparanase
splice variant, T5, endowed with protumorigenic characteristics. FASEB J
2010, 24:1239–1248.
12. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I,
Abramovitch R: Heparanase promotes growth, angiogenesis and
survival of primary breast tumors. Int J Cancer 2006, 118:1609–1617.
13. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N:
Heparanase induces vascular endothelial growth factor expression:
correlation with p38 phosphorylation levels and Src activation.
Cancer Res 2006, 66:1455–1463.
14. Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, Vlodavsky I,
Elkin M: Function of heparanase in prostate tumorigenesis: potential for
therapy. Clin Cancer Res 2008, 14:668–676.
15. Basche M, Gustafson D, Holden S, O’Bryant CL, Gore L, Witta S, Schultz MK,
Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K,
Addison RS, Moore JC, Eckhardt SG: Phase I biological and pharmacologic
study of the heparanase inhibitor PI-88 in patients with advanced solid
tumors. Clin Cancer Res 2006, 12:5471–5480.
16. Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoreto M,
Cassinelli G, Lanzi C, Pisano C, Ilan N, Vlodavsky I, Zunino F: Pre clinical
and clinical significance of heparanase in Ewing’s sarcoma. J Cell Mol
Med 2011, 15:1857–1864.
17. Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S: Multicentre
phase I\II study of PI-88, a heparanase inhibitor in combination with
docetaxel in patients with castrate-resistant prostate cancer. Ann Oncol
2010, 21:1302–1307.
18. Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB,
Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R:
A phase II study of the heparanase inhibitor PI-88 in patients with
advanced melanoma. Invest New Drugs 2008, 26:89–94.
19. Cassinelli G, Lanzi C, Tortoreto M, Cominetti C, Petrangolini G, Favini E,
Zaffaroni N, Pisano C, Penco S, Vlodavsky I, Zunino F: Antitumor efficacy of
the heparanase inhibitor SST0001 alone and in combination withantiangiogenic agents in the treatment of human pediatric sarcoma
models. Biochem Pharmacol 2013, 10:1424–1432.
20. Singer S, Maki RG, O’Sullivan B: Soft tissue sarcoma. In DeVita, Hellman, and
Rosenberg’s Cancer: Principles and Practice of Oncology. 9th edition. Edited by
DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA.
Philadelphia PA, USA: Lippincott Williams & Wilkins; 2011:Chapter 115.
21. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S,
Flugelman MY, Vlodavsky I, Ilan N: Processing and activation of latent
heparanase occurs in lysosomes. J Cell Sci 2004, 117:2249–2258.
22. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N: Heparanase
augments epidermal growth factor receptor phosphorylation: correlation
with head and neck tumor progression. Cancer Res 2008, 68:10077–10085.
23. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, Doweck I:
Heparanase induces VEGF C and facilitates tumor lymphangiogenesis.
Int J Cancer 2008, 123:2566–2573.
24. Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M: Heparanase
activity in alveolar and embryonal rhabdomyosarcoma: implications for
tumor invasion. BMC Cancer 2009, 9:304.
25. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, Pappo O:
Expression of heparanase in normal, dysplastic, and neoplastic human
colonic mucosa and stroma. Evidence for its role in colonic
tumorigenesis. Am J Pathol 2000, 157:1167–1175.
26. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I,
Zimmermann A, Buchler MW: Heparanase expression in primary and
metastatic pancreatic cancer. Cancer Res 2001, 61:4655–4659.
27. Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, Fan M, Prinz RA,
Xu X: Heparanase-1 expression is associated with the metastatic potential
of breast cancer. Surgery 2002, 132:326–333.
28. Wang LL, Yustein J, Louis C, Russell HV, Pappo AS, Paulino A, Nuchtern JG,
Chintagumpala M: Solid Tumors of Childhood. In DeVita, Hellman, and
Rosenberg’s Cancer: Principles and Practice of Oncology. 9th edition. Edited by
DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA.
Philadelphia PA, USA: Lippincott Williams & Wilkins; 2011:Chapter 123.
doi:10.1186/1756-9966-33-39
Cite this article as: Kazarin et al.: Expression of heparanase in soft tissue
sarcomas of adults. Journal of Experimental & Clinical Cancer Research
2014 33:39.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
